Can surgical adhesives may cause false positivity in follow-up positron emission tomography after lung cancer resection?

Rıza DOĞAN¹(ID)
Serkan UYSAL¹(ID)
Ulaş KUMBASAR²(ID)
Deniz KÖKSAL³(ID)
Burcu ANCIN⁴(ID)
Murat TUNCEL⁵(ID)

¹ Department of Thoracic Surgery, Hacettepe University School of Medicine, Ankara, Turkey
² Hacettepe Üniversitesi Tıp Fakültesi, Göğüs Cerrahisi Anabilim Dalı, Ankara, Türkiye
³ Department of Cardiothoracic Surgery, Yale University School of Medicine, New Haven, United States of America
⁴ Yale Üniversitesi Tıp Fakültesi, Göğüs Kalp Damar Cerrahisi Anabilim Dalı, New Haven, Amerika Birleşik Devletleri
⁵ Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey
⁶ Hacettepe Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye
⁷ Department of Thoracic Surgery, Burdur State Hospital, Ankara, Turkey
⁸ Burdur Devlet Hastanesi, Göğüs Cerrahisi Anabilim Dalı, Ankara, Türkiye
⁹ Department of Nuclear Medicine, Hacettepe University School of Medicine, Ankara, Turkey
¹⁰ Hacettepe Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Ankara, Türkiye

ABSTRACT
Can surgical adhesives may cause false positivity in follow-up positron emission tomography after lung cancer resection?

Introduction: Postoperative complications following thoracic procedures are a major cause of morbidity and mortality. Alveolar air leaks and/or bronchopleural fistulas are associated with increased risk of infection, prolonged chest tube, and hospital stay duration and therefore generate economical concern for health care providers. A variety of surgical sealants or adhesives have been introduced to overcome this complication. Since intraoperative BioGlue® application can also cause an inflammatory reaction and mimic tumor recurrence on FDG PET-CT, in the present study we aimed to investigate its potential role in false-positive PET-CT results in patients operated for NSCLC.

Materials and Methods: Data of six patients who underwent resection for primary NSCLC at our institution (Department of Thoracic Surgery, Hacettepe University Medical Faculty) between January 2015 and December 2018 and had false positivity, due to BioGlue® application, at the bronchial stump in follow-up FDG PET-CT were retrospectively analyzed from a prospectively collected database.
Results: One of the 6 patients was female and 5 were male. The mean age was 68 years (range, 56-79 years). The average time interval between operation and postoperative FDG-PET imaging was 4.3 months (range, 4-6 months). Follow-up FDG-PET imaging SUVmax values ranged between 3.0 and 9.0 (median: 5.33). All patients have been evaluated by FDG-PET scan following the detection of soft tissue densities at the surgical site suspicious for recurrence at their follow-up chest CT scans. Four patients underwent a bronchoscopic examination, bronchial stumps were examined and multiple biopsies were taken from suspicious nodules or tissues and sent for pathologic examination. Histopathological results revealed inflammation which is compatible with foreign body granuloma, without any suspicion for malignancy, in all cases. Two patients were solely followed-up and subsequent FDG-PET imaging after 3 months revealed complete resolution of FDG uptake.

Conclusion: To avoid unnecessary biopsies or surgical procedures, the possibility of false-positive results due to surgical adhesive product use should be taken into account while interpreting follow-up FDG-PET imaging results and the operative reports should be written in detail, describing which surgical materials were used and their exact application sites.

Key words: Surgical adhesives; lung cancer; surgery; pet-ct

INTRODUCTION

Postoperative complications following thoracic procedures are a major cause of morbidity and mortality. Patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC) are usually elderly, smoker, have poor nutritional status and associated comorbidities, and thus have a greater risk of developing pulmonary complications (1). Amongst these complications, Alveolar air leaks and/or bronchopleural fistulas are associated with increased risk of infection, prolonged chest tube, and hospital stay duration and therefore generate economical concern for health care providers (2,3). In recent years, a variety of surgical sealants or adhesives have been introduced to overcome this complication (4-7). BioGlue® (CryoLife International Inc., Kennesaw, GA, USA) is one of these adhesives and applied in a variety of surgical specialties including thoracic surgery. It is a synthetic material composed of purified bovine serum albumin (BSA) and glutaraldehyde and causes an inflammatory reaction following application which ends up with granulation tissue formation (3,8,9).

Recurrence of NSCLC after surgical treatment is reported to be loco-regional in nearly 30% of cases and usually presents as nodules involving the parenchymal or bronchial stump staple lines (10). Accurate detection of these recurrences is crucial regarding the...
initiation of adjuvant therapies to increase survival. Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)-computed tomography (CT) is a follow-up imaging tool often obtained for restaging or detection of residual/recurrent disease (11). Although it is highly sensitive for the detection of these recurrences, its specificity is limited due to the increased FDG uptake caused by the inflammation of the healing stumps during the postoperative period (12,13). Since intraoperative BioGlue® application can also cause an inflammatory reaction and mimic tumor recurrence on FDG PET-CT, in the present study we aimed to investigate its potential role in false-positive PET-CT results in patients operated for NSCLC.

MATERIALS and METHODS

Data of six patients who underwent resection for primary NSCLC at our institution (Department of Thoracic Surgery, Hacettepe University Medical Faculty) between January 2015 and December 2018 and had false positivity, due to BioGlue® application, at the bronchial stump in follow-up FDG PET-CT were retrospectively analyzed from a prospectively collected database. The study was approved by the ethical committee of Hacettepe University Medical Faculty. Patients’ data were collected including the following variables: sex, age, type of resection, location of the lesion, the time interval between operation and postoperative FDG-PET imaging, post-resection FDG-PET findings, diagnostic bronchoscopy results, fine needle aspiration biopsy (FNAB) results, and overall outcome.

FDG PET-CT Imaging Protocol

Patient Preparation

The patients fasted for at least 6 hours before the injection. Images were acquired 60 minutes after an injection of approximately 370 ± 32 MBq of FDG. Patients were asked to void their bladders before imaging to reduce bladder activity.

Imaging protocol

All patients underwent PET-CT imaging from the skull base to the upper thigh with six to seven-bed positions (3 min/bed) on a PET-CT scanner. PET images were acquired in a 3D mode with a 128×128 matrix and a low-dose CT that was used for attenuation correction. An iterative reconstruction algorithm (two iterations, twenty-one subsets) followed by a post-reconstruction smoothing Gaussian filter was used for image reconstruction.

Image Review/Interpretation

FDG PET-CT images were reviewed for areas of abnormally increased tracer uptake by an experienced nuclear medicine physician who was blinded to the findings of conventional and structural imaging. For visual analysis, FDG PET-CT uptake was considered abnormal if it was located outside the normal anatomical structures or if the intensity of uptake was greater than that in the background and could not be identified as physiological activity (4). The maximum standardized uptake value (SUV$_{max}$) of each lesion suspicious for recurrence was calculated.

The presence or absence of disease was confirmed by either histopathological examination or follow-up with imaging methods.

Surgical Procedure

BioGlue® was applied to 32 patients who had a history of incomplete fissure, advanced emphysematous parenchyma and who took neoadjuvant chemotherapy during the same period. All patients have undergone major lung resection (lobectomy) for non-small-cell lung carcinoma (NSCLC) by the same surgeon via an open thoracotomy technique. The same amount (5 mL) and brand of (BioGlue®) surgical adhesive were used intraoperatively to all patients. All patients achieved R0 resection confirmed by final pathologic examination. Patients were followed up through to December 2019 (Table 1).

RESULTS

One of the 6 patients was female and 5 were male. The mean age was 68 years (range, 56-79 years). The average time interval between operation and postoperative FDG-PET imaging was 4.3 months (range, 4-6 months). Follow-up FDG-PET imaging SUV$_{max}$ values ranged between 3.0 and 9.0 (median: 5.33) (Figure 1). All patients have been evaluated by FDG-PET scan following the detection of soft tissue densities at the surgical site suspicious for recurrence at their follow-up chest CT scans.

Four patients underwent a bronchoscopic examination, bronchial stumps were examined and multiple biopsies were taken from suspicious nodules or tissues and sent for pathologic examination. Histopathological results revealed inflammation which is compatible with foreign body granuloma,
without any suspicion for malignancy, in all cases. Two patients were solely followed-up and subsequent FDG-PET imaging after 3 months revealed complete resolution of FDG uptake. Patients’ data are shown in Table 2.

### DISCUSSION

Post-operative air leak from a bronchial stump is a major cause of morbidity after lung resections. It may have a detrimental effect on the postoperative course by causing bronchopleural fistulae and consequent infections which may lead to prolonged chest tube drainage and hospital stay, higher healthcare costs, and even life-threatening complication such as post-pneumonectomy empyema (14-16). Many clinicians are seeking studies that were focused on this topic to find potential methods to avoid or reduce this complication. Utilizing synthetic materials such as fibrin sealants, collagen fleece, and synthetic glues to the bronchial stump are some of the preventive methods to overcome this complication (15-18).

BioGlue®, which is a synthetic material composed of purified bovine serum albumin (BSA) and glutaraldehyde, is one of these materials. It produces a stable, solid medium after these two components bind to each other and cause an inflammatory reaction which ends up with granulation tissue formation (3,8,9,19). It is administered to the target area to reinforce the tissues. In all of our cases, BioGlue® was

---

**Table 1. Patient characteristics**

| Age/Gender | Performed operation | cTNM | Neoadjuvant Chemoteraphy/ Radiotheraphy | Pathology | Emphysema/ Incomplet Fissure |
|------------|---------------------|------|----------------------------------------|----------|----------------------------|
| 69/M       | RLL+LND             | T1N0M0 | +/-                                    | Adenocarcinoma     | +/-          |
| 56/M       | RUL+LND             | T1N0M0 | +/-                                    | Squamous carcinoma | +/-          |
| 79/M       | RML+LND             | T1N2M0 | +/-                                    | Adenocarcinoma     | +/-          |
| 71/F       | RUL+LND             | T1N0M0 | +/-                                    | Adenocarcinoma     | +/-          |
| 73/M       | LUL+LND             | T2N2M0 | +/-                                    | Squamous carcinoma | +/-          |
| 63/M       | RUL+LND             | T2N2M0 | +/-                                    | Adenocarcinoma     | +/-          |

RLL: Right lower lobectomy, RML: Right middle lobectomy, RUL: Right upper lobectomy, LUL: Left upper lobectomy, LND: Lymph node dissection.

**Table 2. Patient characteristics after surgery**

| Age/Gender | pTNM | PET interval sup (month) | SUV max value | Histopathologic result (with FNAB) | Outcome        |
|------------|------|--------------------------|---------------|-----------------------------------|----------------|
| 69/M       | T1N0M0 | 4                        | 3.2           | Chronic inflammation              | Alive, no recurrence |
| 56/M       | T1N0M0 | 4                        | 5.31          | Chronic inflammation              | Alive, no recurrence |
| 79/M       | T1N0M0 | 4                        | 3.0           | Chronic inflammation              | Alive, no recurrence |
| 71/F       | T1N0M0 | 4                        | 6.6           | Chronic inflammation              | Alive, no recurrence |
| 73/M       | T2N0M0 | 6                        | 5.35          | NA                                | Alive, no recurrence |
| 63/M       | T2N1M0 | 4                        | 9.0           | NA                                | Alive, no recurrence |

PET: Positron emission tomography; SUV max: maximum standard uptake value; FNAB: Fine needle aspiration biopsy.

sup Time interval between operation and follow-up PET imaging.
used as an adjunct to the staple lines on the bronchi-al stump. Following the application of BioGlue® to the target area, an inflammatory response consisting of polymorphonuclear neutrophils, macrophages and granulation tissue occurs. Granulation tissue consequently becomes fibrous scar tissue. However, in rare cases, this healing process is complicated by a chronic foreign body inflammatory reaction triggered by the synthetic material (8,20).

Recurrence is a common phenomenon in the natural history of NSCLC, occurs in 20-80% of patients, and determines their survival (21). Thus, the detection of these recurrences is crucial regarding the initiation of adjuvant therapies to increase survival. The recurrence is described as loco-regional when it occurs where the primary tumor was located, at the bronchial stump, pleura, or chest wall (22).

FDG-PET is a useful follow-up imaging tool used for restaging or detection of residual/recurrent disease in patients with NCSLC. Although it is highly sensitive for the diagnosis of recurrent disease, anatomic information and the exact localization of the suspicious findings may be lacking. Besides, treatment-distorted anatomy and the increased FDG uptake caused by the inflammation of the healing stumps during the postop-erative period may end up with false-positive results and hamper the correct diagnosis of recurrences (11-13,23). Additionally, false-positive results have also been reported due to foreign body inflammatory reactions to surgical materials such as textile or metal elements, non-absorbable sutures, synthetic surgical adhesives, metal staples, Teflon and talc (20,24). In this report, we present 6 cases who had undergone pulmonary resection for NSCLC and obtained false-positive FDG-PET results due to foreign body reactions during their follow-up period. All patients exhibited granulomatous foreign body reactions after administration of BioGlue® to their bronchial staple lines during pulmonary resection. Four out of 6 patients the inflammatory reaction was confirmed by histopathologic examination. We followed 2 patients as their follow up chest computed tomography (CT) findings were low suspicious for recurrence. Subsequently, their SUV_{max} uptake values improved after 3 months. In total, we applied BioGlue® in 32 cases with variable amounts (5 cc in 8 and 2 cc in 24 cases). Although, in all cases with false PET positivity the amount of BioGlue® applied were 5 cc it is difficult to interpret with this limited data whether the amount of glue has an impact on false positivity.

CONCLUSION
To sum up, to avoid unnecessary biopsies or surgical procedures, the possibility of false-positive results due to surgical adhesive product use should be taken into account while interpreting follow-up FDG-PET imaging results and the operative reports should be written in detail, describing which surgical materials used and their exact application sites.

Ethical Committee Approval: The approval for this study was obtained from Hacettepe University Clinical Research Ethic Committee (Decision no: 2020/05-13, Date: 25.02.2020).

CONFLICT of INTEREST
The authors of this meta-analysis declare that they have no conflict of interest.

AUTHORSHIP CONTRIBUTIONS
Concept/Design: RD
Analysis/Interpretation: SU, UK, RD, DK, MT
Data Acquisition: RD, SU, BA, UK
Writing: RD, UK, SU, MT
Clinical Revision: RD, UK, SU
Final Approval: RD

REFERENCES
1. Rock P, Rich PB. Postoperative pulmonary complications. Curr Opin Anaesthesiol 2003: 16(2): 123-31.
2. Wood DE, Lauer LM, Layton A, Tong KB. Prolonged length of stay associated with air leak following pulmonary resec tion has a negative impact on hospital margin. Clinicoecm Outcomes Res. 2016;8:187-95.
3. Tsilimigras DI, Antonopoulou A, Ntanasis-Stathopoulos I, Patrini D, Papagiannopoulos K, Lawrence D, et al. The role of BioGlue in thoracic surgery: a systematic review. J Thorac Dis 2017; 9(3): 568-76.
4. Anegg U, Lindenmann J, Matzi V, Smolle J, Maier A, Smolle-Juttner F. Efficiency of fleece-bound sealing (TacchoSil) of air leaks in lung surgery: a prospective randomised trial. Eur J Cardiothorac Surg 2007; 31(2): 198-202.
5. Belcher E, Dusmet M, Jordan S, Ladas G, Lim E, Goldstraw P. A prospective, randomized trial comparing BioGlue and Vivostat for the control of alveolar air leak. J Thorac Cardiovasc Surg 2010; 140(1): 32-8.
6. Dango S, Lin R, Hennings E, Passlick B. Initial experience with a synthetic sealant PleuraSeal after pulmonary resec tions: a prospective study with retrospective case matched controls. J Cardiothorac Surg 2010;5:50.
Surgical adhesives and false positivity in lung cancer

7. Petter-Puchner AH, Simunek M, Redl H, Puchner KU, Van Griensven M. A comparison of a cyanoacrylate [corrected] glue (Glubran) vs. fibrin sealant (Tisseel) in experimental models of partial pulmonary resection and lung incision [corrected] in rabbits. J Invest Surg 2010; 23(1): 40-7.

8. Herget GW, Kassa M, Riede UN, Lu Y, Brethner L, Hasse J. Experimental use of an albumin-glutaraldehyde tissue adhesive for sealing pulmonary parenchyma and bronchial anastomoses. Eur J Cardiothorac Surg 2001; 19(1): 4-9.

9. Tansley P, Al-Mulhim F, Lim E, Ladas G, Goldstraw P. A prospective, randomized, controlled trial of the effectiveness of BioGlue in treating alveolar air leaks. J Thorac Cardiovasc Surg 2006; 132(1): 105-12.

10. Caulo A, Mirsadraee S, Maggi F, Leccisotti L, van Beek EJ, Bonomo L. Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria. Eur Radiol 2012; 22(3): 588-606.

11. Sudarski S, Henzler T, Schoenberg SO. Post-therapeutic positron emission tomography/computed tomography for early detection of non-small cell lung cancer recurrence. Transl Lung Cancer Res 2013; 2(4): 293-303.

12. Keidar Z, Haïm N, Guralnik L, Wollner M, Bar-Shalom R, Ben-Nun A, et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004; 45(10): 1640-6.

13. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995; 36(5): 788-93.

14. Belboul A, Dernevik L, Aljassim O, Skrbic B, Radberg G, Roberts D. The effect of autologous fibrin sealant (Vivostat) on morbidity after pulmonary lobectomy: a prospective randomised, blinded study. Eur J Cardiothorac Surg 2004; 26(6): 1187-91.

15. Belda-Sanchis J, Serra-Mitjans M, Iglesias Sentis M, Rami R. Surgical sealant for preventing air leaks after pulmonary resections in patients with lung cancer. Cochrane Database Syst Rev 2010(1): CD003051.